Explore All 633 Divestiture Medical Products Deals - Search the Database Free
M&A Deal Summary |
|
|---|---|
| Date | December 13, 2023 |
| Target | Acclarent |
| Sector | Medical Products |
| Buyer(s) | Integra LifeSciences |
| Sellers(s) | Ethicon Endo-Surgery |
| Deal Type | Divestiture |
| Deal Value | 275M USD |
FILTER BY
| Category | Company |
|---|---|
| Founded | 1989 |
| Sector | Medical Products |
| Employees | 4,396 |
| Revenue | 1.6B USD (2024) |
Integra LifeSciences is a major medical technology dedicated to limiting uncertainty for surgeons, so they can concentrate on providing the best patient care. Integra offers innovative solutions in orthopedic extremity surgery, neurosurgery, and reconstructive and general surgery. Integra LifeSciences was founded in 1989 and is based in Princeton, New Jersey.
| Deal Context for Buyer | # |
|---|---|
| Overall | 45 of 45 |
| Sector: Medical Products | 38 of 38 |
| Type: Divestiture | 12 of 12 |
| State: California | 9 of 9 |
| Country: United States | 38 of 38 |
| Year: 2023 | 1 of 1 |
| Size (of disclosed) | 3 of 27 |
| DATE | TARGET | DEAL TYPE | VALUE |
|---|---|---|---|
| 2022-12-01 |
SIA
Chicago, Illinois, United States SIA is a commercial-stage medical device company, committed to raising the standard of care in plastic, reconstructive, and general surgery and lowering systemic costs through “for surgeon, by surgeon” medical device innovation. The company’s flagship product family, DuraSorb Monofilament Mesh is on the market and indicated for use in the reinforcement of soft tissues where weakness exists. DuraSorb was specifically designed for plastic, reconstructive, and general surgery and is US FDA 510(k) cleared and CE marked. SIA was formed in 2016 and is based in Chicago, Illinois. |
Buy | - |
Ethicon Endo-Surgery (EES) has an endless supply on hand. A subsidiary of Johnson & Johnson, the company makes surgical devices and equipment for open surgeries and minimally invasive procedures in the areas of bariatrics, gastrointestinal health, gynecology, and surgical oncology.
| Deal Context for Seller | # |
|---|---|
| Overall | 3 of 3 |
| Sector: Medical Products | 3 of 3 |
| Type: Divestiture | 3 of 3 |
| State: California | 1 of 1 |
| Country: United States | 2 of 2 |
| Year: 2023 | 1 of 1 |
| Size (of disclosed) | 1 of 1 |
| DATE | TARGET | DEAL TYPE | VALUE |
|---|---|---|---|
| 2019-02-13 |
Auris Health
Redwood City, California, United States Auris Health, Inc. is a developer of robotic technologies, initially focused on lung cancer, with an FDA-cleared platform currently used in bronchoscopic diagnostic and therapeutic procedures. Redwood City, California. Auris Health was founded in 2007 and is based in Redwood City, California. |
Buy | $3.4B |
